# Cardiovascular Disease (CVD) Phenotyping Core

> **NIH NIH P01** · EMORY UNIVERSITY · 2023 · $317,836

## Abstract

PROJECT SUMMARY / ABSTRACT: Cardiovascular Disease (CVD) Phenotyping Core
 The Cardiovascular Disease (CVD) Phenotyping Core will be responsible for advanced subclinical and
clinical CVD phenotyping of all participants enrolled in the Precision Cardiovascular Phenotyping and
Pathophysiological Pathways in the CARRS cohort (Precision-CARRS) program project grant (PPG).
Responsibilities include providing coordination, expertise, and standardization of all elements related to the
proposed phenotyping. The overarching goal of the Core is to obtain the highest quality of CVD subclinical and
clinical phenotyping in this cohort and further train existing teams and standardize protocols for (a) novel
advanced CVD phenotyping in the field, (b) cardiovascular imaging in central facilities, (c) centralized
interpretation of all tests, (d) adjudication of subclinical and clinical CVD events and mortality, (e) blood and
urine testing and laboratory services, together with quality assurance and quality control. The CVD
Phenotyping Core will be based in Delhi, India and will consolidate and augment existing infrastructure and
expertise and leverage a decade of collaborative experience between Emory and India’s leading health
research institutions. Specific Aim 1 is to formulate and implement plans for accurate and reproducible
phenotyping of sub-clinical CVD that includes measures of (i) functional vascular disease assessed as pulse
wave velocity and augmentation index that reflect arterial stiffness; (ii) coronary artery calcium, a reflection of
subclinical coronary atherosclerosis; (iii) carotid intima-media thickness and plaque; (iv) hepatic steatosis; and
(v) sub-clinical myocardial dysfunction measured as left ventricular systolic or diastolic dysfunction using
cardiac echo. Aim 2 will implement plans to standardize adjudication of prevalent and incident clinical CVD
events to include atherosclerotic events and occurrence of heart failure. Atherosclerotic events will include
incident cardiovascular death, myocardial infarction, and stroke or transient ischemic attacks. Secondary
outcomes include diagnosis of angina or coronary or peripheral arterial disease, and revascularization. Heart
failure occurrences will include diagnosis of symptomatic Stage C or D heart failure. In Aim 3, we will formulate
and implement laboratory sample collection and analysis for all biomarkers analyses, to include traditional risk
factors, advanced lipid and metabolic measures, and circulating proteins that reflect activation of
pathophysiologic processes associated with CVD. The Core will work in close coordination with the
Administrative and Field Coordination Core which will administer the field logistics. Acquired data will be
transferred to the Data Management and Analysis Core, and provide curated CVD phenotyping data to all 4
PPG projects.

## Key facts

- **NIH application ID:** 10622452
- **Project number:** 5P01HL154996-02
- **Recipient organization:** EMORY UNIVERSITY
- **Principal Investigator:** Dorairaj Prabhakaran
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $317,836
- **Award type:** 5
- **Project period:** 2022-05-15 → 2027-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10622452

## Citation

> US National Institutes of Health, RePORTER application 10622452, Cardiovascular Disease (CVD) Phenotyping Core (5P01HL154996-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10622452. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*